Please ensure Javascript is enabled for purposes of website accessibility

Here's Why AnaptysBio Shares Are Slipping Today

By Cory Renauer - Aug 20, 2019 at 4:46PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

An executive's departure at a sensitive time has investors nervous.

What happened

Shares of AnaptysBio (ANAB -0.76%), a clinical-stage biotechnology company, fell in response to the imminent departure of Dominic Piscitelli, the company's CFO since 2017. Investors were worried that Piscitelli's resignation announcement signaled trouble for the company's lead candidate etokimab and pounded the stock 13.6% lower on Tuesday.

So what 

Over the past couple of years, AnaptysBio has shifted the focus for etokimab, a potential first-in-class IL-33 inhibitor, away from peanut allergy prevention and toward the treatment of eczema, chronic sinusitis, and asthma. Shifting focus isn't necessarily bad but it doesn't inspire confidence, either. In June, AnaptysBio shares fell after Regeneron (REGN 1.47%) announced disappointing results from a clinical trial with another IL-33 inhibitor.

Woman with glasses, high heels, and business outfit looking at a red downward sloping arrow that's crashing through the ground.

Image source: Getty Images.

As a pre-commercial company, AnaptysBio needs to get a new drug application into the hands of the Food and Drug Administration (FDA) as soon as possible. Following signals that don't bode well for etokimab's future, the abrupt departure of a CFO ahead of some important readouts has been taken as a sign of trouble.

Now what

There are two midstage clinical trials with etokimab scheduled to read out before the end of the year. Investors should realize that right now, independent data monitors are the only people who know which patients received etokimab and which were given placebos. That means Piscitelli shouldn't have any more knowledge about etokimab's upcoming results than the rest of us.

While the abrupt departure of an executive at this pivotal time is somewhat troubling, odds are that Piscitelli's simply reacting to another job offer. If investors are looking for potential signs of trouble with etokimab, increasing activity around AnaptysBio's less advanced pipeline is probably a more accurate signal.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

AnaptysBio Stock Quote
$20.97 (-0.76%) $0.16
Regeneron Pharmaceuticals, Inc. Stock Quote
Regeneron Pharmaceuticals, Inc.
$655.01 (1.47%) $9.49

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/16/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.